Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic rivaroxaban in high-risk heart failure without atrial fibrillation
ChiCTR2200062238Phase 4Not yet recruiting
- Sponsor
- China-Japan Union Hospital of Jilin University
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of rivaroxaban in heart failure (HF) (2 arms), sponsored by China-Japan Union Hospital of Jilin University. Primary endpoint: Thromboembolic events. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
rivaroxaban
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on ChiCTR2200062238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062238.